Powerful myeloma treatment regimen shows promise for AL amyloidosis

Two studies published today in Blood, the Journal of the American Society of Hematology (ASH), demonstrate preliminary success of an effective multiple myeloma (MM) regimen in patients with AL amyloidosis, a rare and devastating blood disease that results in deposition of damaging abnormal protein in critical organs of the body, including the kidneys, heart, liver, and intestines, and shares some characteristics with MM.

The combination of , cyclophosphamide, and dexamethasone (CyBorD, or CVD) is a recently discovered but already widely used MM that produces rapid and profound responses. Because of its success in MM, recent investigations have explored the use of this regimen as a potential therapy for AL amyloidosis, since those with the disease have few treatment options. Currently, the most effective treatment for AL amyloidosis is high-dose and autologous stem cell transplant; however, most patients are ineligible for this aggressive and difficult to tolerate approach due to organ damage common in patients with the disease.

Fortunately for AL amyloidosis patients, there is hope for a better treatment. Each of the studies summarized below conclude that treatment with the novel CyBorD/CVD regimen can lead to complete hematologic response and may allow AL amyloidosis patients to become eligible for stem cell transplants and live longer, higher quality lives.

STUDY 1: Cyclophosphamide-Bortezomib-Dexamethasone (CYBORD) Produces Rapid and Complete Hematological Response In Patients with AL Amyloidosis
First Author: Joseph Mikhael, MD, Mayo Clinic, Scottsdale, AZ

Background

Retrospective analysis of 17 patients with confirmed and symptomatic AL amyloidosis treated with CyBorD prior to autologous stem cell transplant (ASCT), as an alternative to high-dose therapy for those deemed ineligible, and as salvage for those with prior therapy
Results

94% hematologic response rate observed in patients
Three patients originally not eligible for ASCT became eligible after treatment
Conclusion

CyBorD produces rapid and complete hematologic responses in the majority of patients with AL amyloidosis regardless of previous treatment or ASCT candidacy and is well tolerated with few side effects. In addition, results demonstrate that the regimen may also allow ASCT non-eligible patients to become eligible after treatment.

STUDY 2: Cyclophosphamide, Bortezomib and Dexamethasone Therapy in AL Amyloidosis is Associated with High Clonal Response Rates and Prolonged ProgressionFree Survival
First Author: Christopher Venner, MD, National Amyloidosis Centre, University College London Medical School, London, United Kingdom

Background

of 43 patients with AL amyloidosis treated with CVD upfront or at relapse
Results

81.4% hematologic response rate observed in patients
Conclusion

CVD is a highly effective combination for the treatment of AL with high hematologic responses. In addition, rapid improvement in organ function was observed and functional organ improvement may potentially allow deferred in previously ineligible patients due to increased organ response.

More information: bloodjournal.hematologylibrary… blood-2011-11-390930
bloodjournal.hematologylibrary… blood-2011-10-388462

Provided by American Society of Hematology

not rated yet
add to favorites email to friend print save as pdf

Related Stories

One step closer in finding treatment for amyloidosis

Oct 21, 2010

University College London scientists funded by the Medical Research Council (MRC) have devised a new approach to treatment of amyloidosis, according to new research published yesterday in Nature.

Recommended for you

Suppressing a protein reduces cancer spread in mice

3 hours ago

Scientists have found that decreasing the levels of or blocking a specific protein commonly found in humans and many other animals allowed them to slow the spread of two different kinds of cancer to the lungs ...

Bone loss drugs may help prevent endometrial cancer

13 hours ago

A new analysis suggests that women who use bisphosphonates—medications commonly used to treat osteoporosis and other bone conditions—have about half the risk of developing endometrial cancer as women who do not use the ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.